Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.

Berk, Michael; Fitzsimons, Joanna; Lambert, Timothy; Pantelis, Christos; Kulkarni, Jayashri; Castle, David; Ryan, Elizabeth W; Jespersen, Sean; McGorry, Pat; Berger, Gregor; Kuluris, Bill; Callaly, Tom; Dodd, Seetal

Berk, Michael; Fitzsimons, Joanna; Lambert, Timothy; Pantelis, Christos; Kulkarni, Jayashri; Castle, David; Ryan, Elizabeth W; Jespersen, Sean; McGorry, Pat; Berger, Gregor; Kuluris, Bill; Callaly, Tom; Dodd, Seetal.

Affiliation

Berk M; Department of Clinical and Biomedical Sciences, Barwon Health, The University of Melbourne, Geelong, Melbourne, Victoria, Australia.

CNS Drugs ; 21(2): 117-27, 2007.

Article in En | MEDLINE | ID: mdl-17284094

Subject(s)

Antipsychotic Agents/adverse effects; Antipsychotic Agents/blood; Clozapine/adverse effects; Clozapine/blood; Agranulocytosis/chemically induced; Antipsychotic Agents/therapeutic use; Australia/epidemiology; Clozapine/therapeutic use; Consensus; Diabetes Mellitus/chemically induced; Humans; Hyperlipidemias/chemically induced; Neutropenia/chemically induced; Population Surveillance; Psychotic Disorders/drug therapy; Weight Gain/drug effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antipsychotic Agents / Clozapine Type of study: Guideline / Screening_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: CNS Drugs Journal subject: FARMACOLOGIA / NEUROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2007 Type: Article Affiliation country: Australia

Search on Google

XML

PubMed Links